

AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims.

1-24. (Cancelled)

25. (Currently amended) A method for ~~adjunctively~~ treating major depressive disorder in an individual who is not fully responsive to conventional therapy, ~~in need thereof~~ comprising administering to the individual an effective amount of exo-S-mecamylamine or a salt thereof, which is substantially free of exo-R-mecamylamine; and at least one additional agent selected from a tricyclic antidepressant, a monoamine oxidase inhibitor, a selective serotonin reuptake inhibitor, a selective norepinephrine reuptake inhibitor, a serotonin-norepinephrine reuptake inhibitor, a norepinephrine dopamine reuptake inhibitor, ~~[[or]]~~ and other antidepressant.

26. (Previously presented) The method of claim 25, wherein the major depressive disorder is single episode major depressive disorder or recurrent episode major depressive disorder.

27. (Previously presented) The method of claim 26, wherein the major depressive disorder is a refractory disorder.

28. (Cancelled)

29. (Previously presented) The method of claim 25, wherein:

(a) the tricyclic antidepressant is doxepin, amitriptyline, amoxapine, clomipramine, desipramine, imipramine, maprotiline, nortriptyline, protriptyline, trimipramine, or a salt thereof;

(b) the monoamine oxidase inhibitor is isocaboxazid, phenelzine, tranylcypromine, or a salt thereof;

(c) the selective serotonin reuptake inhibitor is citalopram, clovoxamine, escitalopram, femoxetine, flesinoxan, fluoxetine, fluvoxamine, paroxetine, sertraline, trazodone, zimeldine, or a salt thereof;

(d) the selective norepinephrine reuptake inhibitor is atomoxetine, or a salt thereof;

(e) the norepinephrine dopamine reuptake inhibitor is bupropion or a salt thereof; and

(f) the serotonin-norepinephrine reuptake inhibitor is venlafaxine, duloxetine, or a salt thereof.

30. (Previously Presented) The method of claim 25, wherein the *exo*-S-mecamylamine is *exo*-S-mecamylamine hydrochloride.

31. (Previously Presented) The method of claim 25, wherein the *exo*-S-mecamylamine or salt thereof is administered in a daily amount of from about 0.05 mg to about 15 mg; and the at least one additional agent is administered in a daily amount of from about 10 mg to about 80 mg.

32. (Previously Presented) The method of claim 25, wherein the *exo*-S-mecamylamine or salt thereof is administered once or twice daily; and the at least one additional agent is administered once, twice, three, or four times daily.

33. (Previously Presented) The method of claim 25, wherein the *exo*-S-mecamylamine or salt thereof and the at least one additional agent are administered together or individually.

34. (Previously Presented) The method of claim 25, wherein the at least one additional agent is a selective serotonin reuptake inhibitor, citalopram.

35. (Previously Presented) The method of claim 25, wherein the major depressive disorder is refractory major depressive disorder.

36. (Cancelled)

37. (Previously presented) The method of claim 25, wherein the exo-S-mecamylamine or salt thereof is administered orally.

38. (New) The method of claim 27, wherein the refractory disorder is selective serotonin reuptake inhibitor-treated major depression.